Abstract
Multiple system atrophy (MSA) is a fatal progressive neurodegenerative disease. Biomarkers are urgently required for MSA to improve the diagnostic and prognostic accuracy in clinic and facilitate the development and monitoring of disease-modifying therapies. In recent years, significant research efforts have been made in exploring multidimensional biomarkers for MSA. However, currently few biomarkers are available in clinic. In this review, we systematically summarize the latest advances in multidimensional biomarkers for MSA, including biomarkers in fluids, tissues and gut microbiota as well as imaging biomarkers. Future directions for exploration of novel biomarkers and promotion of implementation in clinic are also discussed.
Author supplied keywords
Cite
CITATION STYLE
Wan, L., Zhu, S., Chen, Z., Qiu, R., Tang, B., & Jiang, H. (2023, December 1). Multidimensional biomarkers for multiple system atrophy: an update and future directions. Translational Neurodegeneration. BioMed Central Ltd. https://doi.org/10.1186/s40035-023-00370-0
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.